既往接种新冠mRNA疫苗基础免疫的日本健康成人接种第一剂和第二剂NVX-CoV2373(TAK-019)疫苗加强针的免疫原性与安全性1年随访:3期开放标签试验最终报告
这项3期单臂开放标签试验在150名既往接种新冠mRNA基础免疫的日本成人中评估两剂NVX-CoV2373加强针(间隔5个月)的免疫原性与安全性。1年随访显示两剂加强针均诱导持久抗SARS-CoV-2免疫应答,未发现新的安全性问题,感染病例均为轻/中度。
要点
- 两剂NVX-CoV2373加强针间隔5个月接种,1年随访时血清IgG和中和抗体滴度仍相对高于加强前水平。
- 1年随访期间两研究部分均无死亡或导致研究终止的不良事件。
- 主要部分SARS-CoV-2感染报告率为14.0%(21/150),扩展部分为10.9%(14/129),所有病例均为轻/中度。
核心结论
- 两剂NVX-CoV2373加强针在每剂接种后诱导持久抗SARS-CoV-2免疫应答长达1年,预期可在日本成人中持续预防SARS-CoV-2感染和重症结局。
- 未发现新的安全性问题,在健康日本参与者中显示出预期的可接受安全性特征。
研究设计与样本
- 3期、单臂、开放标签试验(NCT05299359),纳入既往接种新冠mRNA基础免疫的日本成人。
- 主要部分第1天接种第一剂NVX-CoV2373加强针,扩展部分第1天接种第二剂,两剂间隔5个月。
- 150名参与者接种第一剂加强针,129名接种第二剂加强针,主要部分17名完成、扩展部分121名完成1年随访。
主要发现
- 主要部分抗SARS-CoV-2血清IgG应答于第29天达峰,扩展部分于扩展第15天达峰;血清中和抗体应答分别于第15天和扩展第29天达峰。
- 两研究部分血清IgG和中和抗体滴度在1年随访期间相对第1天和扩展第1天加强前滴度保持相对较高。
- 主要部分SARS-CoV-2感染报告率为14.0%(21/150),扩展部分为10.9%(14/129),所有病例均为轻/中度。
- 两研究部分1年随访期间均无死亡或导致研究终止的不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In this phase 3, single-arm, open-label trial in Japanese adults who had previously received a COVID-19 mRNA primary vaccination (NCT05299359), two NVX-CoV2373 boosters, administered 5 months apart in the main and extension parts of the study, respectively, induced robust immune responses up to day (D) 15 after each dose. This final report presents immunogenicity and safety findings at 1-year follow-up. METHODS: Immunogenicity of the first NVX-CoV2373 booster (main part) and second NVX-CoV2373 booster (extension part) was assessed at D29, D91, D181, and D366 in each study part. Safety findings were evaluated for each study part at 1-year follow-up. RESULTS: Of 150 participants who received a first NVX-CoV2373 booster on D1, 21 did not participate in the extension part and 17 completed the main part. In total, 129 participants received a second booster on extension day (ED) 1, and 121 completed the extension part. In the main and extension parts, anti-SARS-CoV-2 serum immunoglobulin G (IgG) responses to the boosters peaked on D29 and ED15, respectively; serum neutralizing antibody (nAb) responses to the boosters peaked on D15 and ED29, respectively. Serum IgG and nAb titres remained relatively high in both study parts throughout the 1-year follow-up compared with their pre-booster titres on D1 and ED1. There were no deaths or adverse events leading to study discontinuation at 1-year follow-up for both study parts. A SARS-CoV-2 infection was reported in 14.0 % (21/150) of participants in the main part and 10.9 % (14/129) in the extension part; all cases were mild/moderate in severity. CONCLUSION: The two NVX-CoV2373 boosters induced durable anti-SARS-CoV-2 immune responses up to 1 year after each dose and are therefore expected to persistently protect against SARS-CoV-2 infections and severe disease outcomes in Japanese adults. No new safety concerns were identified, demonstrating the expected acceptable safety profile in healthy Japanese participants.
引用
- Kuriyama K, Murakami K, Sugiura K, et al. One-year follow-up of the immunogenicity and safety of a first and second booster dose of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Final report of a phase 3 open-label trial. Vaccine. 2025. PMID: 40753673. doi:10.1016/j.vaccine.2025.127562
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。